Australia markets open in 46 minutes

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
44.19-3.65 (-7.63%)
At close: 04:00PM EDT
44.00 -0.19 (-0.43%)
After hours: 06:53PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 5.80B
Enterprise value 5.56B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)14.32
Price/book (mrq)29.83
Enterprise value/revenue 14.03
Enterprise value/EBITDA -11.23

Trading information

Stock price history

Beta (5Y monthly) 0.89
52-week change 3-42.46%
S&P500 52-week change 324.19%
52-week high 394.75
52-week low 319.83
50-day moving average 357.62
200-day moving average 351.26

Share statistics

Avg vol (3-month) 31.32M
Avg vol (10-day) 31.23M
Shares outstanding 5120.58M
Implied shares outstanding 6121.29M
Float 881.27M
% held by insiders 113.14%
% held by institutions 195.42%
Shares short (15 Apr 2024) 410.67M
Short ratio (15 Apr 2024) 49.39
Short % of float (15 Apr 2024) 410.27%
Short % of shares outstanding (15 Apr 2024) 48.85%
Shares short (prior month 15 Mar 2024) 410.59M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -133.29%
Operating margin (ttm)-57.74%

Management effectiveness

Return on assets (ttm)-41.73%
Return on equity (ttm)-290.14%

Income statement

Revenue (ttm)396.59M
Revenue per share (ttm)3.34
Quarterly revenue growth (yoy)545.90%
Gross profit (ttm)N/A
EBITDA -515.34M
Net income avi to common (ttm)-528.63M
Diluted EPS (ttm)-4.45
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)355.54M
Total cash per share (mrq)2.95
Total debt (mrq)110.93M
Total debt/equity (mrq)57.03%
Current ratio (mrq)3.10
Book value per share (mrq)1.63

Cash flow statement

Operating cash flow (ttm)-594.73M
Levered free cash flow (ttm)-404.84M